ENTITY
Tasly Biopharmaceuticals

Tasly Biopharmaceuticals (TASLY HK)

2
Analysis
Health CareHong Kong

Refresh
17 Jul 2019 09:52

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters

Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...

Logo
842 Views
Share
No more insights
x